NCT03877809View on ClinicalTrials.gov

Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Beta-Thalassemia
Interventions
DRUG

Sirolimus 0.5 mg

Daily administration of 1 or more tablets

Trial Locations (2)

44121

Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, Ferrara

44124

Department of Growth and Reproduction Azienda Ospedaliero-Universitaria S.Anna, Ferrara

All Listed Sponsors
collaborator

Università degli Studi di Ferrara

OTHER

lead

Rare Partners srl Impresa Sociale

OTHER

NCT03877809 - Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients | Biotech Hunter | Biotech Hunter